Press release material from Globe Newswire. AP News staff was not involved in its creation.
click to copy
CALGARY, Alberta, June 21, 2022 (Globe Newswire) — ResverLogix Corp (“ResverLogix”, or “Corporation”) (TSX: RVX) held its annual meeting of shareholders (“Meeting”) today in Calgary, Alberta. ,
In the course of business proceedings at the meeting, shareholders elect five (5) board members until the next annual meeting. The voting results for the shares represented at the meeting for the individual directors were as follows:
|to vote||votes withheld||to percentage||percentage withheld|
|Donald J McCaffrey||125,007,142||7,326,179||94.46%||5.54%|
|Siu Lun (Dickie) To||127,354,197||4,979,124||96.24%||3.76%|
Resverlogix shareholders meeting of May 11, 2022 (“Information Circular”) and approved all resolutions set forth in the Notice of Management Information Circular. The Information Circular is available on SEDAR at www.sedar.com, and on the Resverlogix website at www.resverlogix.com.
A webcast archive of the executive presentation portion of the meeting will be available here.
Founded in 2001, Resverlogix is a Calgary-based late-stage biotechnology company and a world leader in epigenetics, or gene regulation, with the goal of developing first-in-class treatments to benefit patients with chronic disease.
Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve the lives of patients by restoring biological functions – from severe diseases such as cardiovascular disease – to returning to a healthy state.
The company’s clinical program is focused on evaluating cardiovascular disease and related comorbidities, and apabetalone, the leading epigenetic candidate for the treatment of COVID-19.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).
For further information please contact:
Email: [email protected]